YHB Investment Advisors Inc. Reduces Holdings in Thermo Fisher Scientific Inc. (TMO)

YHB Investment Advisors Inc. cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 21.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 76,914 shares of the medical research company’s stock after selling 21,167 shares during the quarter. Thermo Fisher Scientific comprises 3.1% of YHB Investment Advisors Inc.’s portfolio, making the stock its 4th biggest position. YHB Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $17,213,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Thermo Fisher Scientific by 1.2% in the third quarter. Vanguard Group Inc. now owns 29,271,095 shares of the medical research company’s stock valued at $7,144,489,000 after purchasing an additional 347,836 shares during the last quarter. Vanguard Group Inc boosted its holdings in Thermo Fisher Scientific by 1.2% in the third quarter. Vanguard Group Inc now owns 29,271,095 shares of the medical research company’s stock valued at $7,144,489,000 after purchasing an additional 347,836 shares during the last quarter. BlackRock Inc. boosted its holdings in Thermo Fisher Scientific by 0.9% in the third quarter. BlackRock Inc. now owns 25,233,243 shares of the medical research company’s stock valued at $6,158,932,000 after purchasing an additional 226,824 shares during the last quarter. Capital World Investors boosted its holdings in Thermo Fisher Scientific by 19.2% in the third quarter. Capital World Investors now owns 15,412,242 shares of the medical research company’s stock valued at $3,761,820,000 after purchasing an additional 2,482,783 shares during the last quarter. Finally, FMR LLC boosted its holdings in Thermo Fisher Scientific by 18.5% in the third quarter. FMR LLC now owns 6,499,139 shares of the medical research company’s stock valued at $1,586,310,000 after purchasing an additional 1,016,082 shares during the last quarter. Institutional investors own 86.92% of the company’s stock.

NYSE:TMO traded up $1.11 during trading hours on Friday, reaching $239.97. 64,748 shares of the stock were exchanged, compared to its average volume of 2,140,164. The company has a quick ratio of 1.27, a current ratio of 1.84 and a debt-to-equity ratio of 0.66. Thermo Fisher Scientific Inc. has a 52 week low of $194.51 and a 52 week high of $253.91. The company has a market cap of $95.17 billion, a PE ratio of 25.29, a P/E/G ratio of 1.54 and a beta of 1.08.



Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 24th. The medical research company reported $2.62 EPS for the quarter, topping analysts’ consensus estimates of $2.55 by $0.07. Thermo Fisher Scientific had a return on equity of 16.49% and a net margin of 10.75%. The company had revenue of $5.92 billion for the quarter, compared to the consensus estimate of $5.70 billion. During the same quarter last year, the business posted $2.31 EPS. Thermo Fisher Scientific’s quarterly revenue was up 15.7% compared to the same quarter last year. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 11.05 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, January 15th. Stockholders of record on Monday, December 17th will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date is Friday, December 14th. Thermo Fisher Scientific’s payout ratio is 7.17%.

TMO has been the subject of a number of analyst reports. Barclays increased their price target on Thermo Fisher Scientific from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, January 3rd. Goldman Sachs Group downgraded Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Monday, September 17th. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $274.00 price target for the company in a report on Monday, October 1st. UBS Group began coverage on Thermo Fisher Scientific in a report on Tuesday, October 9th. They set a “buy” rating and a $295.00 target price on the stock. Finally, Citigroup increased their target price on Thermo Fisher Scientific from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, October 10th. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus price target of $271.10.

In other news, insider Gregory J. Herrema sold 17,235 shares of the stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $247.00, for a total transaction of $4,257,045.00. Following the sale, the insider now directly owns 26,446 shares in the company, valued at approximately $6,532,162. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Williamson sold 9,500 shares of the stock in a transaction that occurred on Friday, December 7th. The stock was sold at an average price of $241.45, for a total value of $2,293,775.00. Following the sale, the chief financial officer now owns 44,124 shares in the company, valued at $10,653,739.80. The disclosure for this sale can be found here. Insiders have sold a total of 32,607 shares of company stock worth $7,972,085 over the last quarter. Insiders own 0.49% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/01/11/yhb-investment-advisors-inc-reduces-holdings-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: What is a Call Option?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply